Organization

Pancreatic Disease Center

1 abstract

Abstract
Perioperative fuzuloparib plus mFOLFIRINOX for resectable pancreatic adenocarcinoma: A phase 1 study.
Org: Pancreatic Disease Center, Shanghai Jiao Tong University School of Medicine,